H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Kura Oncology (KURA – Research Report) today and set a price target of $40.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including Kura Oncology’s strong financial position and promising clinical developments. The company ended the year with a robust cash reserve of $727.4 million, bolstered by a significant upfront payment from its partnership with Kyowa Kirin. This financial strength is expected to support Kura’s ongoing and future clinical trials, including the anticipated NDA submission for ziftomenib in the second quarter of 2025.
Additionally, Kura’s commitment to advancing its clinical-stage programs, particularly with ziftomenib, tipifarnib, and KO-2806, is a key factor in Pantginis’s positive outlook. The recent positive data from the KOMET-001 trial and the alignment with regulators for the upcoming Phase 3 KOMET-017 trial underscore the potential of ziftomenib as a best-in-class treatment for AML. The company’s strategic focus on expanding into new indications, such as GIST and diabetes, further enhances its growth prospects, making it an attractive investment opportunity.
Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Viking Therapeutics, and Esperion. According to TipRanks, Pantginis has an average return of -5.2% and a 29.38% success rate on recommended stocks.
In another report released today, Barclays also maintained a Buy rating on the stock with a $32.00 price target.